Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,709 total articles
Spyre Therapeutics reported strong Part A induction results for SPY001 in ulcerative colitis (9.2-point Robarts histology improvement; 40% clinical remission; 51% endoscopic improvement), and is now enrolling Part B. The stock pulled back after a $300M common-share offering was announced, creating a tradeable setup. We favor a mid-term long (45 tra…
Commvault (CVLT) looks actionable on takeover speculation and supportive analyst momentum. Fundamentals show healthy cash flow and outsized ROE, while the float is compact and short interest remains meaningful. We upgrade to a Buy for a mid-term swing trade and lay out entry, stop and target.
Cisco (CSCO) is exposed to accelerating AI and optical networking demand from hyperscalers and large enterprises. Strong free cash flow, a healthy balance sheet and improving technicals support a long directional trade. Entry $82.34, stop $76.00, target $95.00 over a 180 trading day horizon.
Euroseas (ESEA) trades at a deep P/E and modest PB despite rising charter rates, a growing yield and improving technicals. With a tight float, active short interest and recent time-charters on fuel-efficient feeders, this is a tactical long for patient investors willing to hold through shipping seasonality.
Intel's recent rally and newfound role as a major AI supply partner have the stock trading like a structural-growth story. With a market cap near $327B, improved technicals, and key catalysts ahead, there's a high-risk, high-reward trade to capture a potential re-rating similar to what Micron experienced. This idea lays out entry, stop, targets, ho…
SentinelOne is trading at a materially cheaper multiple than a year ago while still showing healthy revenue growth and positive free cash flow. With enterprise demand for AI-aware endpoint security picking up after recent high-profile AI threat stories, the downside is limited relative to upside from multiple expansion and margin inflection. This t…
FUCHS SE (FUPEF) has shown virtually no breakout after years of sideways performance while recent momentum metrics have become extreme. Elevated short interest and near-zero average daily volume create a dangerous cocktail for both longs and shorts, but the technical picture and mean-reversion logic argue for a disciplined short trade over the next…
Fortinet's pullback has left the stock trading near multi-month lows while core fundamentals remain intact: solid free cash flow ($2.226B trailing), healthy ROA/ROE, and a direct line into mandated enterprise spending from post-quantum cryptography upgrades. Valuation looks full on headline multiples but the risk-reward for a mid-term long is attra…
Redwire (RDW) is a modular space-infrastructure supplier that just landed a string of high-profile contracts and is showing early signs of margin expansion. Market cap sits near $1.9B and the stock is trading above its short-term moving averages, but the company remains unprofitable and free cash flow is negative. This idea lays out a mid-term swin…
Harrow (HROW) recently saw heightened headline activity - a small 8.625% note sale and a large block sale by a 10% holder - that appears to have pushed sentiment too far. Fundamentals (reaffirmed 2025 revenue guidance of $270-280M, positive free cash flow ~$43M) and technicals (price above the 10/20-day SMAs; heavy short interest that could fuel co…
Duolingo has rebuilt the plumbing that converts engagement into durable revenue. With 52.7M daily active users, record $1.04B revenue and $414M net profit in 2025, the market is pricing in a long slog of weak monetization. We think that's too pessimistic. Behavioral design, new premium AI tiers and stronger ARPU mechanics create a clear path to hig…
Western Midstream (WES) offers an 8.9% yield, steady free cash flow of roughly $1.5B, and valuation metrics that leave room for a modest re-rate. This trade targets capital appreciation plus income over a 180-trading-day horizon with a controlled stop to protect against distribution or commodity-driven shocks.
Tarsus is translating FDA approval into cash flow. Net product sales surged to $451.4M in 2025 with gross margins near 93%, and the stock sits above key moving averages with bullish momentum. This is a tactical long for investors willing to back continued commercial execution and pipeline progress over the next 45 trading days.
Austal (AUTLF) remains a Strong Buy. The stock is technically digesting recent selling while momentum signals are turning constructive and short activity is elevated — a setup that can produce outsized rebounds. Our trade plan targets a near-term rally to $4.25 from an entry at $3.27, with a strict stop at $2.90. Free cash flow volatility and execu…
Kelly Services (KELYA) is trading well below historical highs with value multiples, a solid free cash flow print and low leverage. This trade targets a mean-reversion move as new sales leadership and steady staffing demand unlock better top-line momentum and multiple expansion. Entry, stop and target laid out for a mid-term (45 trading days) trade.
We turn neutral on Strategic Education (STRA) after a read-through from customer-acquisition issues at Phoenix Education Partners. STRA's cash flow and dividend look stable, and valuation (roughly 14x EPS, EV/EBITDA ~6.7) is reasonable. Still, recent technicals, elevated short activity, and the prospect of enrollment softness argue for stepping asi…
monday.com trades at a market cap near $3.25B after a steep multi-month derating. The business remains a modern, sticky SaaS work operating system with recurring revenue, reasonable trailing P/E of 26x, and a float that still supports rally potential given elevated short interest. This trade idea proposes a long entry at the current price with a $9…
Premium Brands has been on my watchlist for a year. A recent pullback finally offers a disciplined entry with asymmetric upside: stable cash generation, margin recovery levers and ongoing consolidation in specialty foods. This trade lays out an actionable entry at $50.00, a protective stop at $42.00, and a 180-day target of $70.00 with clear cataly…
FNF is priced like a deep housing collapse, but balance-sheet strength, $5.68B in free cash flow and a meaningful dividend make the downside limited and upside compelling over the next 45 trading days. Upgrade to a tactical long with a defined entry, stop and target.
Perdoceo Education combines double-digit revenue growth, healthy margins and a clean balance sheet with active capital return. At current levels the shares look reasonably valued for continued execution; this trade idea targets upside to $45 while limiting downside with a $30 stop.
ASM International looks positioned to capture another multi-year growth leg as leading foundries push into 2nm. With a $43.6B market cap, tidy buyback activity, and bullish technicals, we upgrade ASMIY to Buy and lay out an actionable long trade with a clear entry, stop, and target.
Eurofins (ERFSF) trades around $75 with neutral momentum but bullish MACD and rising short interest. For traders looking for a mid-term swing, a disciplined long with entry at $75.00, stop at $70.00 and a $88.00 target balances upside (roughly 17%) against liquidity and execution risk.
Lyft looks inexpensive on several traditional metrics while short interest remains elevated. An oil-driven spike in rideshare demand and visible short-volume concentration create a plausible short-squeeze setup. This is a tactical, medium-horizon trade that pairs a fundamental valuation backdrop with a technical squeeze trigger; manage position siz…
NerdWallet (NRDS) is showing continued top-line growth and strong free cash flow generation even as organic-search headwinds persist. The stock trades near $10.65 with EV/EBITDA ~5.4 and free cash flow of $130.3M; this combination supports a mid-term long trade to $15 with a tight stop at $9.50.
Teva is trading like a commoditized generics company while recent biosimilar approvals, dual filing acceptance for an anti-IgE biosimilar, and a $400M strategic financing for an inflammatory-disease asset argue for a re-rate. EV/EBITDA of ~9.95 and $1.15B in free cash flow leave room for multiple expansion if commercial execution and regulatory out…
